|

Donanemab Clinical Trials

2 actively recruiting trials across 1 location

Also known as: (LY3002813), LY3002813

Pipeline

Phase 3: 1

Top Sponsors

  • Eli Lilly and Company2

Indications

  • Alzheimer's Disease2
  • Alzheimer Disease2
  • Tauopathies1
  • Mental Disorders1
  • Neurodegenerative Diseases1

Other1 trial

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Phase 3

Huntsville, Alabama1 trial

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

Rehabilitation & Neurological Services

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.